Literature DB >> 19725747

Feasibility study of autofluorescence mammary ductoscopy.

Alexandre Douplik1, Wey L Leong, Alexandra M Easson, Susan Done, George Netchev, Brian C Wilson.   

Abstract

We report the technical feasibility of autofluorescence ductoscopy in the ex-vivo setting. The current imaging algorithm for visualizing tumor tissue against the normal tissue background, although developed and optimized for other organs, appears to provide discrimination between intraductal tumor and normal ductal tissue. Point fluoroscopy is also performed. Although the optical "geometry" for this is different, the findings are consistent with the imaging observations.

Entities:  

Mesh:

Year:  2009        PMID: 19725747     DOI: 10.1117/1.3210773

Source DB:  PubMed          Journal:  J Biomed Opt        ISSN: 1083-3668            Impact factor:   3.170


  4 in total

Review 1.  Comparison of ductoscopy, galactography, and imaging modalities for the evaluation of intraductal lesions: a critical review.

Authors:  Ozgur Sarica; Enis Ozturk; Huseyin C Demirkurek; Fatih Uluc
Journal:  Breast Care (Basel)       Date:  2013-10       Impact factor: 2.860

2.  Normalized autofluorescence imaging diagnostics in upper GI tract: a new method to improve specificity in neoplasia detection.

Authors:  Ekaterina Krauss; Abbas Agaimy; Alexandre Douplik; Heinz Albrecht; Helmut Neumann; Arndt Hartmann; Ralf Hohenstein; Martin Raithel; Eckhart G Hahn; Markus F Neurath; Jonas Mudter
Journal:  Int J Clin Exp Pathol       Date:  2012-10-20

3.  Use of fiberoductoscopy for the management of pathological nipple discharge: ten years follow up of a single center in China.

Authors:  Chao Zhang; Jie Li; Hongchuan Jiang; Mengxin Li
Journal:  Gland Surg       Date:  2020-12

4.  Detection of breast cancer precursor lesions by autofluorescence ductoscopy.

Authors:  Laurien Waaijer; Mando D Filipe; Janine Simons; Carmen C van der Pol; Tjeerd de Boorder; Paul J van Diest; Arjen Joost Witkamp
Journal:  Breast Cancer       Date:  2020-07-28       Impact factor: 4.239

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.